Biodistribution of lymphokine‐activated killer (LAK) cells in WAG rats after hepatic‐artery or jugular‐vein infusion
暂无分享,去创建一个
[1] E. Wisse,et al. Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and kupffer cells in the liver of rats treated with continuous infusion of interleukin‐2 , 1990, Hepatology.
[2] P. Kuppen,et al. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. , 1990, British Journal of Cancer.
[3] J. Hiserodt,et al. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. , 1990, Cellular immunology.
[4] W. Linehan,et al. Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.
[5] S. Rosenberg. Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review. , 1989, Cancer treatment reviews.
[6] H. Wallny,et al. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes , 1989, The Journal of experimental medicine.
[7] F. Ramsdell,et al. Generation of lymphokine-activated killer cell activity from non-NK precursor cells. , 1988, Cellular immunology.
[8] A. Maghazachi,et al. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. , 1988, Cellular immunology.
[9] R. Puri,et al. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. , 1988, Journal of the National Cancer Institute.
[10] A. Maghazachi,et al. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells , 1988, The Journal of experimental medicine.
[11] A. Eggermont,et al. The requirements for successful immunotherapy of intraperitoneal cancer using interleukin‐2 and lymphokine‐activated killer cells , 1987, Cancer.
[12] J. Ortaldo,et al. Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.
[13] S. Rosenberg,et al. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. , 1986, Journal of immunology.
[14] S. Rosenberg,et al. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.
[15] S. Rosenberg,et al. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. , 1985, Journal of immunology.
[16] S. Rosenberg,et al. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.
[17] S. Rosenberg,et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.
[18] D. Mathisen,et al. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.
[19] Ackerman Nb,et al. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. , 1970 .
[20] C. Breedis,et al. The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.